Author Archives: Nicole Wetsman

RG7916 Safe for Infants With Type 1 SMA, Early Data Indicate

Early interim data from a Phase 2 clinical trial evaluating varying doses of a potential oral therapy, RG7916, in infants with type 1 spinal muscular atrophy (SMA) is showing good safety and tolerability, researchers said in a recent scientific presentation. Preliminary findings of 13 babies enrolled…